Pfizer is a Big Pharma Buy The accompanying table presents an overview of big pharma companies, presented in descending order by market cap. My favorite play in the space remains to be Pfizer (PFE), which I have written about previously and finally bought shares today at $17.90 with a dividend yield exceeding 7%. Despite growth concerns and looming generic competition for Lipitor in late 2011, I bought shares of Pfizer today as a value pick and turnaround play which operates in a defensive sector with a strong balance sheet. Also, the Company is aggressively cutting costs and buying back its shares on the open market. Despite weakness in most of the 14 big pharma stocks presented in the table, it is unlikely ...